Feasibility of an approach in which treatment of high phosphate levels with phosphate binders in dialysis patients is based on preferences of the patient.

Phase 1

• Conditions: Chronic kidney disease, End-stage renal disease; MedDRA version: 23.1Level: LLTClassification code 10076412Term: Chronic kidney disease stage 5System Organ Class: 100000004857; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2019-003698-24-NL
• Lead Sponsor: Amsterdam UMC, location VUmc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-04-12
• Last Update Posted: 8 October 2021

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

-Age = 18 years
-Haemodialysis patients (since at least 3 months)
-Necessity of phosphate binding therapy
-Written informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 25
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 15

Exclusion Criteria

-Intolerance to one of three types of phosphate binders
-Expected cessation of dialysis treatment within six months

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified